Out of Patients EP445: Fatal to Relentless: Kathy Giusti

The rational question sits in plain view. Why does a patient need to behave like an executive operator to survive a diagnosis that the system claims it can manage?

That question explains why Kathy Giusti’s story carries weight beyond inspiration. In 1996, she received a diagnosis of multiple myeloma with a projected survival of 3 years. She worked in the pharmaceutical industry. She understood enough to recognize that the system surrounding her did not operate with urgency, coordination, or accountability. She also understood something more uncomfortable. The system behaved exactly as designed.

At that time, cancer research followed a fragmented model. Academic centers controlled data and tissue. Investigators competed for publication priority. Pharmaceutical companies advanced compounds based on portfolio economics, not disease burden alone. Nonprofits raised money to fund research but rarely functioned as operational engines. Regulators evaluated submissions that reflected those fragmented inputs. Each actor optimized for its own incentives. No single entity held responsibility for accelerating outcomes across the disease.

Patients entered that system as the least informed participant with the highest personal risk.

Giusti responded by building the Multiple Myeloma Research Foundation. She did not build a support group. She built an operating model that attempted to align incentives across stakeholders. She convened academic centers. She funded research. She aggregated data. She worked with industry and regulators. She pushed for speed.

Her approach reflects a core truth that the broader healthcare conversation often avoids. Progress follows incentive alignment, not moral clarity.

The system she entered in 1996 rewarded fragmentation. Academic institutions protected data because publications drive tenure and funding. Pharmaceutical companies prioritized assets with clear commercial potential. Regulators required evidence but did not control how that evidence emerged. Nonprofits competed for donor attention and brand identity. Each behavior made sense in isolation. Together they slowed progress.

Giusti’s intervention focused on coordination. She increased the number of researchers working in myeloma. She created shared data infrastructure. She attracted industry attention to a previously neglected disease. She raised capital to fund these efforts. Public claims attribute more than $600 million raised and involvement in more than 15 drug approvals. The exact attribution for each outcome requires careful parsing. What matters for analysis is the mechanism. She increased the probability that research translated into approved therapies by reducing friction between actors.

That mechanism matters because it reveals how the system produces both progress and harm.

Consider how incentives shape patient experience at diagnosis. A patient receives abnormal lab results. The law now requires that results enter a patient portal immediately. The intent centers on transparency. The consequence places the burden of interpretation on the patient. The physician remains in clinic. The patient turns to search engines. Information asymmetry shifts but does not disappear. It relocates to a different moment in the care journey.

Giusti described sitting on a bookstore floor reading medical textbooks to understand her disease. Today a patient opens a browser and encounters an overwhelming volume of information with varying quality. The technology improved. The burden shifted. The system still expects the patient to bridge the gap.

That expectation reflects a deeper structural issue. Healthcare reimbursement rewards services delivered, not comprehension achieved. No billing code captures the value of a patient who understands their disease well enough to navigate treatment effectively. Yet that understanding directly influences outcomes.

Giusti’s framework encourages patients to act as the chief executive of their own care. That concept resonates because it reflects reality. It also reveals a misalignment. A system that requires executive level decision making from patients without providing equivalent support creates unequal outcomes. Patients with education, time, and resources perform better. Patients without those assets absorb greater risk.

The system does not explicitly intend that inequality. It emerges from incentive design.

Consider clinical trial access. Trials represent both a treatment option and a research mechanism. Participation often depends on geographic proximity to academic centers, physician awareness, and patient capacity to travel. Sponsors design trials to meet regulatory endpoints efficiently. Sites select patients based on inclusion criteria and operational feasibility. The result favors patients who can navigate complexity.

Giusti emphasized the importance of genomic sequencing, biomarker testing, and advanced diagnostics. Those tools enable precision medicine. They also introduce cost and access challenges. Insurance coverage varies. Out of pocket costs can reach thousands of dollars. Patients who secure these diagnostics gain a more precise treatment path. Patients who do not rely on standard protocols.

Again, the system behaves rationally. Payers manage cost exposure. Providers deliver billable services. Manufacturers price products based on market dynamics. Patients absorb the consequences of gaps between those incentives.

The system also produces measurable progress. Survival rates for multiple myeloma improved significantly over the past 30 years. New therapies including immunomodulatory drugs, proteasome inhibitors, and CAR T cell therapies expanded treatment options. Data infrastructure improved. Collaboration increased. Those outcomes reflect aligned incentives in specific areas.

The tension lies in how those gains distribute across populations.

Giusti addressed disparities in African American communities, which face higher incidence of multiple myeloma. Historical abuses such as the Tuskegee study created distrust in medical research. That distrust interacts with current barriers to trial participation and access to specialized care. The system acknowledges these issues. It struggles to resolve them because no single actor owns the outcome.

Nonprofits can fund outreach. Academic centers can design inclusive trials. Sponsors can set diversity targets. Regulators can issue guidance. Each step helps. None alone resolves the structural barrier. Incentives still prioritize speed to approval and return on investment.

The system claims patient centricity. Its behavior reveals prioritization of throughput, revenue, and risk management.

Giusti’s career illustrates both the potential and the limits of operating within that system. She achieved significant acceleration in research and drug development. She also relied on partnerships with the same institutions whose incentives create friction. She navigated that tension by aligning interests where possible.

Her own reflections suggest evolution. She described earlier years characterized by urgency and intensity. She now speaks about warmth and reflection after reviewing decades of personal journals. That shift mirrors the maturation of the field. Early stages required disruption and acceleration. Current stages require optimization and integration.

The next phase of oncology will depend on how incentives evolve around data, artificial intelligence, and longitudinal patient management.

Data represents the central asset. High quality longitudinal datasets that integrate genomic, clinical, and outcome information enable better treatment decisions and faster research. Building those datasets requires coordination and funding. Maintaining them requires governance around access and privacy. Monetizing them introduces tension between public good and private return.

Artificial intelligence introduces additional complexity. AI models require large datasets. They promise improved diagnostics and treatment recommendations. They also concentrate power among organizations that control data and computational resources. The risk lies in replicating existing inequities at scale.

Patients again occupy the position of both contributor and beneficiary of these systems. They provide data. They receive recommendations. They rarely control how value distributes.

Giusti expressed interest in working with AI partners who demonstrate genuine commitment to patient outcomes. That perspective reflects an attempt to shape incentives through collaboration. It also highlights the absence of formal mechanisms to ensure alignment.

The system will not correct these issues through moral appeals. It will respond to changes in financial and regulatory incentives.

Several levers exist.

Payment models can reward outcomes rather than volume. Value based care initiatives attempt to move in this direction. Implementation remains uneven. Measuring outcomes accurately and fairly presents challenges. Aligning incentives across payers, providers, and manufacturers requires coordination. Regulatory frameworks can incentivize data sharing. Requirements for interoperability and standardized data formats can reduce fragmentation. Enforcement and funding determine effectiveness. Public and private investment can support infrastructure that benefits multiple stakeholders. Shared data platforms, trial networks, and patient navigation tools can reduce duplication of effort. Governance models must balance access with sustainability. Employer sponsored insurance can influence demand. Employers bear a significant portion of healthcare costs. They can push for transparency, quality metrics, and access to specialized care. Their incentives align with productivity and cost control. Patients and advocacy organizations can shape narratives and priorities. Their influence depends on organization, credibility, and ability to engage with policy and industry leaders.

The question remains how to align these levers toward patient protection while maintaining economic viability.

Giusti’s model offers one example. She created value for multiple stakeholders. Researchers gained funding and collaboration. Industry gained access to data and trial networks. Regulators engaged with coordinated evidence. Patients gained access to new therapies. Donors gained a clear mission. That alignment enabled progress.

Scaling that model across diseases and systems presents challenges. It requires leadership that understands both science and incentives. It requires trust among stakeholders with competing interests. It requires sustained funding.

It also requires acknowledging limits. No model will eliminate uncertainty in cancer care. Biology introduces variability that no system can fully control. The goal shifts from eliminating risk to managing it more effectively.

The system currently manages risk unevenly. Patients absorb a disproportionate share through financial burden, information gaps, and delayed access. Aligning incentives toward earlier detection, coordinated care, and equitable access can reduce that burden.

The cost of inaction remains measurable. Delayed diagnoses increase treatment complexity and cost. Fragmented care leads to redundant testing and avoidable complications. Lack of data sharing slows research. Inequitable access perpetuates disparities.

These costs affect not only patients but also employers, payers, and public budgets. Aligning incentives toward patient protection can improve economic efficiency. Early detection and appropriate treatment reduce long term costs. Coordinated care improves outcomes and reduces waste.

The system does not require reinvention. It requires adjustment of incentives that already drive behavior.

Giusti’s story demonstrates that individuals can influence those incentives. It also demonstrates that sustained change depends on institutional alignment.

The next phase of healthcare reform will depend less on rhetoric and more on design. Stakeholders must identify where current incentives misalign with desired outcomes and adjust accordingly. That work demands precision, data, and willingness to challenge existing structures.

Patients should not need to become executives to survive. Until incentives align, many will continue to do exactly that.